GLP-1 receptor agonists, including semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound), are now among the most prescribed medications in the country. As more patients arrive in PT clinics on these drugs, clinicians need a working understanding of how they affect the musculoskeletal system.
What Are GLP-1 Medications?
GLP-1 (glucagon-like peptide-1) receptor agonists were originally developed for type 2 diabetes management. They lower blood glucose by stimulating insulin secretion and suppressing appetite. High-dose formulations have since received FDA approval for chronic weight management. Patients on these medications lose weight, sometimes rapidly and significantly. That weight loss, while often metabolically beneficial, carries musculoskeletal implications that PTs need to account for.
The Muscle Loss Problem
Clinical trials on GLP-1 drugs consistently show that a meaningful portion of weight lost is lean mass, not just fat. Data on semaglutide suggests 25 to 40 percent of total weight loss may come from muscle tissue. Tirzepatide shows similar patterns, though some protocols that pair the medication with structured resistance training show better lean mass retention.
This matters clinically for several reasons:
- Patients may present with reduced strength relative to their body weight and activity history.
- Functional capacity may be lower than expected for age and baseline.
- Sarcopenia risk increases, particularly in older adults or those who already have low muscle mass.
- Rapid weight loss without adequate protein intake accelerates muscle catabolism.
The term “Ozempic body” has entered popular media to describe the appearance of significant muscle loss alongside fat loss. In clinical terms, this pattern reflects low muscle mass with reduced fat-free mass overall. It is a real finding, not a cosmetic concern.
Assessment Implications
When a patient discloses GLP-1 use, adjust your intake and objective testing accordingly.
Strength and functional testing. Standard normative values may not apply to someone who has lost 30 to 50 pounds in six months. Use objective measures: grip strength dynamometry, 30-second chair stand, 4-meter gait speed. These give you a functional baseline that is independent of weight history.
Body composition context. BMI is a poor proxy here. A patient can present at a normal BMI while having significant muscle deficits. If body composition data is available from the prescribing provider, review it. If not, functional strength testing is your best clinical proxy.
Bone density awareness. Emerging data suggests GLP-1 medications may affect bone remodeling, though the evidence is still developing. For older patients with osteoporosis risk factors, flag bone health and adjust loading accordingly.
Nutritional status. GLP-1 drugs suppress appetite significantly, and some patients are not consuming adequate protein to support tissue maintenance or rehab response. Asking about dietary habits, particularly protein intake, is within your scope when it directly affects outcomes. If intake appears severely inadequate, coordinate with the prescribing provider or a registered dietitian.
Rehab Considerations
Resistance training is the most important intervention for patients on GLP-1 medications. Evidence consistently shows that combining GLP-1 therapy with structured resistance exercise reduces lean mass loss and improves functional outcomes compared to medication alone.
Practical guidance for program design:
- Prioritize progressive resistance training over cardio-dominant protocols, especially for older adults.
- Set realistic progression expectations. Patients may fatigue faster than their weight loss would suggest. Deconditioning, muscle loss, and nutritional insufficiency all contribute.
- Monitor for changes in joint loading patterns. Rapid weight loss can alter load distribution at the knee, hip, and foot. Some patients report new joint symptoms as their weight changes.
- Communicate with the prescribing provider if a patient presents with significant functional decline, disproportionate weakness, or rapid muscle loss. These are clinical findings worth reporting.
What to Ask at Intake
Add these questions when a patient reports GLP-1 use:
- How long have you been on the medication?
- How much weight have you lost, and over what timeframe?
- Are you doing any resistance training?
- Have you noticed changes in your strength or endurance?
- Has your diet changed significantly since starting the medication?
The answers directly shape goal-setting, progression planning, and how you communicate expectations to the patient.
Clinical Takeaway
GLP-1 medications are a permanent part of the treatment landscape for obesity and metabolic disease. PTs are well-positioned to address one of the most consistent downsides of these drugs: muscle loss and functional decline. Understanding the mechanism, adjusting your assessment, and building resistance-focused programs are not extra steps. They are standard care for this patient population.